KIT and neoplasm: Motesanib is a highly specific inhibitor of VEGFR1, 2, and 3; of PDGFR, and Kit (Polverino et al, 2006), all of which have been implicated as key regulators of angiogenesis, lymphangiogenesis, and tumour cell proliferation (Heinrich et al, 2002; Ferrara et al, 2003; Yu et al, 2003).